Navigation Links
miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease
Date:12/11/2009

BOULDER, Colo., December 10, 2009 miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, today announced the publication of data demonstrating that microRNA-206 (miR-206) plays a crucial role in the progression of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and in neuromuscular synaptic regeneration in mice. The findings, published in the December 11 issue of the journal Science, reveal miR-206 as a potential target for the development of therapeutic agents for the treatment of neuromuscular disease. The study was conducted by researchers led by Eric N. Olson, Ph.D., at the University of Texas Southwestern Medical Center. miRagen is the exclusive licensee of intellectual property (IP) rights related to this discovery, which are part of the Company's extensive estate of enabled microRNA IP.

"This is a breakthrough with significant implications for human health," said William S. Marshall, Ph.D., President and CEO of miRagen Therapeutics, Inc. "Currently there are no therapies available to ALS patients that will reverse or delay the onset of muscle atrophy associated with this debilitating disease. Uncovering the essential role of miR-206 in neuromuscular maintenance brings us one step closer to the day when physicians will be able to offer hope to those suffering from ALS and other neuromuscular diseases."

"We are, quite frankly, excited by these findings," said Dr. Olson, Chairman and Professor of Molecular Biology at the University of Texas Southwestern Medical Center and miRagen's Chief Scientific Advisor. "One of the hallmarks of ALS and other similarly degenerative muscle diseases is the inability of the neuromuscular synapse to transmit the impulse that leads to muscle contraction. Our data show that miR-206 plays a central regulatory role in this process. We view this as an extremely promising target for therapeutic intervention."


'/>"/>

Contact: Tammy Egan
tegan@miragenrx.com
303-531-5952 x107
miRagen Therapeutics, Inc.
Source:Eurekalert  

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge Semantics , ... at this year’s Bio-IT World Conference and Expo in Boston May 23-25 ... 4.0 solution. The Anzo Smart Data Lake is also a finalist for the ...
(Date:5/22/2017)... ... May 22, 2017 , ... Cancer diagnostics ... in booth B2 at the Association for Pathology Informatics Annual Summit ... addition to demonstrating its Cancer Diagnostic Cockpit and Consultation Portal, Inspirata will present ...
(Date:5/19/2017)... ... May 19, 2017 , ... The University City Science Center ... ripe for commercialization, and who are affiliated with the 21 partner academic and ... QED, now in its tenth round, is the first multi-institutional proof-of-concept program for ...
(Date:5/18/2017)... ROCHELLE, VIRGINIA (PRWEB) , ... May 17, 2017 , ... ... senior business executive and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical ... In addition to his position at Eurofins and Cardinal Health, he was former Chief ...
Breaking Biology Technology:
(Date:3/22/2017)... , March 21, 2017 Optimove ... used by retailers such as 1-800-Flowers and AdoreMe, ... — Product Recommendations and Replenishment. Using Optimove,s machine learning ... personalized product and replenishment recommendations to their customers ... on predictions of customer intent drawn from a ...
(Date:3/20/2017)... 2017 PMD Healthcare announces the release of ... Management System (WMS), a remote, real-time lung health monitoring ... Healthcare is a Medical Device, Digital Health, and Chronic ... creating innovative solutions that empower people to improve their ... PMD developed the first ever personal spirometer, Spiro PD, ...
(Date:3/9/2017)... MELBOURNE , Australia , March ... clinical study data at the prestigious World Lung Imaging ... Dr. Andreas Fouras , was invited to deliver ... and pulmonary medicine. This globally recognised event brings together ... and share the latest developments in lung imaging. ...
Breaking Biology News(10 mins):